Key features and details
- Rabbit polyclonal to Fibrinopeptide A
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Human
- Isotype: IgG
Product nameAnti-Fibrinopeptide A antibody
See all Fibrinopeptide A primary antibodies
DescriptionRabbit polyclonal to Fibrinopeptide A
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Mouse, Human
Full length Human Fibrinopeptide A (AAH20764.1; amino acids 1-218).
- Mouse kidney tissue lysate; Human ovary tissue; Fibrinopeptide A transfected 293T cell lysate
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.4
Constituent: 2.68% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab103648 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Predicted molecular weight: 95 kDa.|
|IHC-P||Use a concentration of 1.5 µg/ml.|
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsThe alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Phosphorylation sites are present in the extracelllular medium.
- Information by UniProt
- A alpha polypeptide antibody
- FGA antibody
- Fib2 antibody
Anti-Fibrinopeptide A antibody (ab103648) at 1 µg/ml + Mouse kidney tissue lysate at 50 µg
Predicted band size: 95 kDa
All lanes : Anti-Fibrinopeptide A antibody (ab103648) at 1 µg/ml
Lane 1 : Fibrinopeptide A transfected 293T cell lysate
Lane 2 : Non-transfected 293T cell lysate
Lysates/proteins at 25 µg per lane.
Predicted band size: 95 kDa
Predicted MWt of AAH20764.1 is 24.70 kDa.
Immunoperoxidase staining of Fibrinopeptide A in formalin-fixed, paraffin-embedded Human ovary using ab103648 at 1.5 ug/ml.
ab103648 has not yet been referenced specifically in any publications.